Business

Alterity Therapeutics to Provide Corporate Update in Fireside Chat

MELBOURNE, Australia and SAN FRANCISCO, June 23, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer of Alterity, will participate in a Fireside Chat hosted by MST Access on Wednesday, 25 June 2025 in Australia / Tuesday, 24 June 2025 in the United States. Dr. Stamler will

articleAlterity Therapeutics Ltd.June 23, 20253/company/alterity-therapeutics-ltd/news/alterity-therapeutics-corporate-fireside-chat-112500449
Alterity Therapeutics to Provide Corporate Update in Fireside Chat

About this update from Alterity Therapeutics Ltd.

[{"type":"image","alt":"ALTERITY THERAPEUTICS LIMITED","displaySize":"","headline":null,"caption":"ALTERITY THERAPEUTICS LIMITED","className":"","disableSlideshowImg":false,"size":{"original":{"width":222,"height":56,"url":"https://media.zenfs.com/en/globenewswire.com/5761c8df20b76a3904e54a7775315c62"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/aH_lC7vKS4YC2ZvHbgCTDQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwNjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/5761c8df20b76a3904e54a7775315c62","width":222,"height":56}},"lazy":false},{"type":"text","content":"MELBOURNE, Australia and SAN FRANCISCO, June 23, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer of Alterity, will participate in a Fireside Chat hosted by MST Access on Wednesday, 25 June 2025 in Australia / Tuesday, 24 June 2025 in the United States. Dr. Stamler will provide a corporate update with a focus on the progress made on the ATH434 development program in Multiple System Atrophy since the Company released positive Phase 2 data in January.","length":687,"tagName":"p"},{"type":"text","content":"Webcast details","length":15,"tagName":"p"},{"type":"table","headerItems":[],"items":[{"val":[{"colspan":"2","style":"vertical-align:bottom;","val":[{"type":"text","content":"AUSTRALIA PARTICIPANTS:","length":23,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"max-width:5%;width:5%;min-width:5%;vertical-align:bottom;","val":[{"type":"text","content":"Date:","length":5,"tagName":"p","attribs":{}}]},{"style":"max-width:95%;width:95%;min-width:95%;vertical-align:bottom;","val":[{"type":"text","content":"Wednesday, 25 June 2025","length":23,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"vertical-align:bottom;","val":[{"type":"text","content":"Time:","length":5,"tagName":"p","attribs":{}}]},{"style":"vertical-align:bottom;","val":[{"type":"text","content":"9:00 a.m. AEST (Sydney/Melbourne)","length":33,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"vertical-align:bottom;","val":[{"type":"text","content":" ","length":6,"tagName":"p","attribs":{}}]},{"style":"vertical-align:bottom;","val":[{"type":"text","content":" ","length":6,"tagName":"p","attribs":...

More updates from Alterity Therapeutics Ltd.

The CompanyMELBOURNE, Australianeurodegenerative diseasesDavid StamlerMultiple System AtrophyAlterityCompany